CGEMCullinan Therapeutics, Inc.
$15.53+150% 1Y
$15.53
$5.7552 weeks$22.98
CGEM as reported
Cullinan Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 7 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2022 · every figure below is as filed, with no scoring applied
- Net income
- −$205M
Net income · −1.0% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2022 · 14 quarters behind |
| Net income | −$205M | −1.0% | Q2 2026 |
| EPS | −$2.84 | n/a | Q3 2024 · 7 quarters behind |
| ROE | −56% | n/a | Q2 2026 |
| ROA | −51% | n/a | Q2 2026 |
| Free cash flow | −$145M | n/a | Q4 2024 · 6 quarters behind |
| P/E | 6.01 | n/a | Q1 2023 · 13 quarters behind |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Cullinan Therapeutics, Inc. (CGEM) · Revenue and profitRevenue and profitCullinan Therapeutics, Inc. (CGEM)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
On our screens:Most shorted stocks